Behice HAN ALMIŞ, Mehmet Hakan TAŞOLAR, Mustafa ÇELİK

Zuklopentiksol dekanoat kullanımından sonra gelişen hipertansif kriz: Depo antipsikotiklere başlamadan önce oral formu başlamanın önemi

Özellikle ilaca uyumsuz şizofreni hastalarında bir tedavi seçeneği olan zuklopentiksol dekanoat depo, etkin ve güvenilir bir antipsikotiktir. Bu yazıda zuklopentiksol dekanoat depo kullanımından sonra gelişen bir hipertansif kriz olgusunu literatürde bir ilk olarak bildirdik. Diğer antipsikotiklerde olduğu gibi zuklopentiksol dekanoat enjeksiyonundan sonra da yaşamı tehdit eden yan etki riski vardır ve depo antipsikotiklerin vücuttan atılması haftalar veya aylar sürdüğü için klinisyenler bir depo antipsikotik ile doğrudan tedaviye başlarken maruz kalınan riskin farkında olmalıdır.

Hypertensive crisis after using zuclopenthixol decanoate: importance of starting oral formulations before starting depot antipsychotics

Zuclopenthixol decanoate depot is an effective and safe antipsychotic which is treatment choice particularly in noncompliant patients with schizophrenia. In this article, a case developing hypertensive crisis after zuclopenthixol decanoate depot is reported first time in the literature. As in other antipsychotics, risk of life threatening adverse effects does exist also after zuclopenthixol decanoate injection and since elimination of depot antipsychotics from the body may take weeks or months, clinicians should be aware of risk imposed by starting therapy directly by a depot antipsychotic.

PDF

___

1. Lublin H, Gerlach J, Hagert U, Meidahl B, Mølbjerg C, Pedersen V, et al. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. Eur Neuropsychopharmacol 1991; 1(4): 541-548.

2. Tuglular I. Atypical Antipsychotİc concept and new horizons in drug treatment of schizophrenia. Bull Clin Psychopharmacol 1999; 9(1):1-13.

3. Cetin M, Ozcubukcuoglu, Tosuner C, Basoğlu C. Efficacy and safety of zuclopenthixol in treatmentresistant schizophrenics. Bull CIin Psychopharmacol 1995; 5(1-4):60-65.

4. Anonymus. WHO-International Society of Hypertension Guidelines for the Managment of Hypertension. J Hypertension 1999; 17:151-183.

5. Angelats EG, Baur EB. Hypertension, Hypertensive crisis, and Hypertensive emergency: approaches to emergency department care. Emergencias 2010;22:209-219.

6. Fontes ML, Varon J. Perioperative hypertensive crisis: newer concepts. Int Anesthesiol Clin 2012; 50(2):40-58

7. Salviato Balbao M, Cecilio Hallak JE, Arcoverde Nunes E, Homem de Mello M, Triffoni-Melo Ade T, Ferreira FI, et al. Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow up. Ther Adv Psychopharmacol 2014; 4(1):30-36.

8. Prasad SE, Kennedy HG. Pseudophaeochromocytoma associated with clozapine treatment. Ir J Psychol Med 2003; 20:132-134.

9. Taylor D, Paton C, Kapur S. Maudsley Prescribing Guidelines in Psychiatry. Eleventh ed., New Jersey: Wiley-Blackwell Pub, 2012.

10. Yasui-Furukori N, Fujii A. Worsened hypertension control induced by aripiprazole. Neuropsychiatr Dis Treat 2013; 9:505-507.

11. Licata G, Scaffidi A. Hypertensive crisis caused by oral administration of sulpiride. Minerva Cardioangiol 1981; 29(5):237-239.

12. Coulter D. Atypical antipsychotics may cause hypertension. 2003. http://www.medsafe.govt.nz/ 12.05.2016

13. Villanueva N, Markham-Abedi C, McNeely C, Diaz FJ, de Leon J. Probable association between ziprasidone and worsening hypertension. Pharmacotherapy 2006; 26(9):1352-1357.